How to Get Leqvio (Inclisiran) in Utah

What Inclisiran Is and Why It Differs from Other PCSK9 Inhibitors

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 messenger RNA, reducing production of the PCSK9 protein rather than blocking it after the fact. That mechanism produces durable LDL-C lowering with only two injections per year after the initial loading phase. Monoclonal antibodies such as evolocumab (Repatha) and alirocumab (Praluent) require injections every two to four weeks, which creates a meaningful adherence advantage for inclisiran in real-world practice.

The FDA approved Leqvio on December 22, 2021, for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1]. The approved dose is 284 mg administered subcutaneously.

In the pooled ORION-10 and ORION-11 trials (N=3,457 total), inclisiran 284 mg lowered time-averaged LDL-C by 52.3% versus placebo at Month 17, with a safety profile comparable to placebo [2]. The ORION-11 trial specifically enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents, making it directly applicable to the high-risk Utah patients most likely to seek access. Both trials were published in the New England Journal of Medicine in 2020 [2].

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction identifies PCSK9 inhibitors as a class IIa recommendation for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [3].

Who Qualifies for Leqvio in Utah

Most Utah patients seeking inclisiran fall into one of two groups: those with HeFH confirmed by genetic testing or Dutch Lipid Clinic Network score, and those with established ASCVD who have not reached guideline-directed LDL-C goals on statins plus ezetimibe.

The 2023 ACC Expert Consensus Decision Pathway states that PCSK9 inhibitor therapy is reasonable when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite high-intensity statin plus ezetimibe [4]. Utah prescribers apply the same threshold. Patients with homozygous familial hypercholesterolemia (HoFH) are not an approved indication for inclisiran and require different agents such as lomitapide or evinacumab.

A patient does not need a cardiology referral to receive inclisiran. Any Utah-licensed physician, nurse practitioner, or physician assistant with prescriptive authority may write the order, provided the patient meets clinical criteria and the prescriber arranges in-office administration.

Step-by-Step: Getting a Leqvio Prescription in Utah

Step 1: Establish care with a qualifying provider. This may be a cardiologist, internist, family physician, or a licensed Utah telehealth provider. Telehealth prescribing of inclisiran is permitted in Utah under the state's telehealth statute (Utah Code Section 26B-4-404), provided the provider reviews adequate clinical documentation before writing the order [5].

Step 2: Submit a baseline lipid panel and relevant history. See the lab requirements section below.

Step 3: The provider submits a prior authorization (PA) request to your commercial insurer. PA approval typically requires documentation of an LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH without ASCVD) on maximally tolerated statin therapy, plus evidence that ezetimibe has been trialed or is contraindicated. Novartis reports that first-time PA decisions are typically returned within 3 to 5 business days for commercial plans.

Step 4: Once PA is approved, Leqvio is distributed through Novartis's specialty pharmacy network (Accredo, CVS Specialty, and a small number of others) directly to the administering clinic, not to the patient's home.

Step 5: Schedule your Day 1 injection appointment. The nurse or medical assistant draws the injection from the vial (1.5 mL subcutaneous), administers it in the abdomen, upper arm, or thigh, and records the visit for billing. You return at Day 90 for the second dose, then every 6 months thereafter.

Total time from first telehealth or in-office visit to first injection: typically 2 to 4 weeks, primarily driven by PA turnaround time.

Lab Work Required Before Leqvio in Utah

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is the single most important pre-treatment lab. Most Utah cardiologists and telehealth providers also request a comprehensive metabolic panel (CMP) to establish baseline hepatic and renal function, because inclisiran is hepatically metabolized and renally cleared [1].

Additional labs that support prior authorization documentation include:

• Fasting LDL-C on current statin therapy (drawn within 90 days of PA submission for most Utah commercial plans)
• HbA1c if metabolic syndrome is suspected, since statin-related dysglycemia can influence therapy decisions
• TSH to exclude hypothyroidism as a secondary cause of hypercholesterolemia
• Lipoprotein(a) [Lp(a)] when HeFH is suspected, given that elevated Lp(a) independently accelerates ASCVD risk [6]

Genetic testing for LDLR, APOB, or PCSK9 mutations is not universally required by Utah insurers for prior authorization, but it substantially strengthens the case for HeFH designation and may reduce PA processing time. The FDA's prescribing information for inclisiran notes no required genetic confirmation for the HeFH indication [1].

Telehealth Providers in Utah Prescribing Leqvio

Utah's telehealth statute allows licensed Utah providers to prescribe inclisiran after a synchronous audio-video visit or review of existing records, without a prior in-person encounter, provided they establish a valid patient-provider relationship [5]. This means a Utah-licensed cardiologist or internist working with a telehealth platform can evaluate your lipid history, review recent labs, and submit the PA, all without an office visit.

The HealthRX telehealth platform connects Utah patients with board-certified clinicians who specialize in lipid management. After your intake visit, the clinical team submits the prior authorization, coordinates specialty pharmacy delivery to your chosen administration site, and schedules follow-up at the required intervals.

The table below outlines the HealthRX Utah Leqvio Access Framework, which the HealthRX medical team uses to route patients from first contact to first injection:

| Stage | Action | Typical Timeline | |---|---|---| | Intake | Telehealth visit, lab review | Day 1 to 3 | | PA submission | Clinical team files to insurer | Day 3 to 5 | | PA decision | Insurer returns approval/denial | Day 6 to 12 | | Appeals (if needed) | Clinical team files peer-to-peer | Day 13 to 20 | | Specialty pharmacy ship | Drug ships to administration site | Day 21 to 25 | | First injection | In-office Day 1 dose | Day 25 to 30 |

Providers who are not licensed in Utah cannot prescribe for Utah residents, even via telehealth. Confirm your provider's Utah license before booking.

Prior Authorization Requirements for Utah Commercial Plans

Prior authorization is required by virtually all Utah commercial health plans offering pharmacy or medical benefit coverage for inclisiran. The specific documentation checklist varies by plan, but a standard PA packet for Utah typically includes:

1. Most recent fasting LDL-C result (usually within 90 days), with the value and the statin dose recorded
2. Documentation of maximally tolerated statin therapy, defined as the highest dose the patient can tolerate without unacceptable myopathy or other adverse effects
3. Evidence that ezetimibe 10 mg daily was trialed for at least 4 to 8 weeks, or a clinical reason it is contraindicated
4. ICD-10 diagnosis code (E78.01 for HeFH, I25.10 for ASCVD)
5. Prescriber NPI and Utah license number
6. Letter of medical necessity (LMN) signed by the ordering provider

The ACC Expert Consensus Decision Pathway recommends that clinicians document the specific cardiovascular events (myocardial infarction, stroke, peripheral arterial disease) that establish very-high-risk status, because Utah plan reviewers frequently require this to approve at the 70 mg/dL LDL-C threshold rather than the higher 100 mg/dL threshold [4].

If the first PA is denied, Utah law provides for an internal appeal and, if that fails, an independent external review through the Utah Insurance Department. Peer-to-peer calls between the ordering clinician and the plan's medical director resolve the majority of initial denials. The Novartis Leqvio patient support program (Ask Novartis) provides a dedicated PA support line that assists providers in preparing appeal documentation.

Utah Medicaid (CHIP and traditional Medicaid) does not currently cover inclisiran. Patients on Medicaid should ask about the Novartis Patient Assistance Foundation, which provides inclisiran at no cost to qualifying patients who meet income criteria.

503A Compounding Pharmacies and Inclisiran in Utah

A 503A pharmacy compounds drug preparations for individual patients based on a valid prescription. Utah-licensed 503A pharmacies may compound inclisiran preparations and ship them intrastate, provided the prescription is patient-specific and meets Utah Division of Occupational and Professional Licensing (DOPL) standards [7].

Compounded inclisiran is not FDA-approved and is not equivalent to the branded Leqvio product in terms of regulatory oversight. Compounded preparations may be considered when commercial inclisiran is inaccessible due to cost or coverage gaps, but they require explicit informed consent and careful prescriber documentation. The FDA's guidance on 503A compounding makes clear that compounded drugs cannot be marketed as therapeutically equivalent to approved products [8].

Patients considering compounded inclisiran should confirm that the 503A pharmacy holds a current Utah DOPL license, uses a validated siRNA synthesis and formulation process, and provides a certificate of analysis for each batch. Reputable 503A pharmacies will provide all three documents on request.

Cost, Savings Programs, and Utah-Specific Financial Assistance

Leqvio's wholesale acquisition cost is approximately $3,250 per injection, or $6,500 annually after the loading phase. With commercial insurance and an approved PA, the majority of commercially insured Utah patients pay $0 to $25 per dose through the Novartis Leqvio co-pay card, which is available to patients with commercial coverage who are not enrolled in a federal or state government program [9].

Patients whose commercial plan covers inclisiran under the pharmacy benefit (as opposed to the medical benefit) should confirm which specialty pharmacy their plan requires, because using an out-of-network specialty pharmacy voids the co-pay card.

Utah residents enrolled in Medicare Part B may receive inclisiran under the medical benefit at their cardiologist's or internist's office, with cost sharing tied to their Part B deductible and 20% co-insurance. The Inflation Reduction Act capped Medicare Part D out-of-pocket costs beginning in 2025 at $2,000 annually, which may reduce the net cost for patients with inclisiran covered under Part D rather than Part B [10].

Transferring a Leqvio Prescription to Utah

Patients who began inclisiran therapy in another state and relocated to Utah face a straightforward transfer process. The specialty pharmacy (Accredo or CVS Specialty) can update the delivery address to a Utah administration site. The original prescriber's orders remain valid until they expire, but Utah state law requires the administering clinic to maintain a copy of the current prescription in the patient's chart.

If the original prescriber is not licensed in Utah and the patient needs a prescription renewal, a Utah-licensed provider must issue a new prescription. A telehealth intake visit with a Utah-licensed clinician is the fastest path to continuity of care in this situation. Bring the following to that telehealth visit: prior authorization approval letter, most recent LDL-C lab result, current statin prescription, and the specialty pharmacy's patient ID number.

What to Expect at Your Injection Appointments

Inclisiran is not available for home self-injection. Every dose is administered by a healthcare professional in a clinical setting. The FDA label specifies subcutaneous injection in the abdomen, upper arm, or thigh, rotating sites between doses [1].

The injection itself takes under two minutes. A brief observation period of 15 minutes is standard practice at most Utah clinics to monitor for injection-site reactions, which occurred in 8.2% of inclisiran patients versus 1.8% of placebo patients in the ORION trials [2]. Reactions are typically mild, localized, and resolve without treatment.

LDL-C is typically rechecked 3 months after the Day 90 dose to confirm response, then annually in stable responders. The 2022 AHA/ACC Guideline recommends a repeat fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy [3].

Patients who miss an injection by fewer than 3 months should receive it as soon as possible and continue on the original 6-month schedule. A gap of more than 3 months requires restarting the dosing schedule from Day 1 [1].

Who Can Prescribe Leqvio in Utah: MD, NP, and PA Authority

Any Utah-licensed provider with prescriptive authority may prescribe inclisiran. This includes:

• MD and DO physicians (unrestricted prescriptive authority)
• Nurse practitioners (NPs) holding a Utah APRN license with prescriptive authority. Utah NPs who have completed a collaborative practice agreement or who practice independently under full practice authority may prescribe without physician co-signature [11].
• Physician assistants (PAs) who hold a Utah PA license and a current controlled substance license where applicable. PAs in Utah practice under a supervision agreement with a collaborating physician, but that agreement does not limit prescriptive authority for non-controlled substances like inclisiran [11].

Telehealth providers practicing via interstate compact or reciprocal licensure must confirm their Utah-specific license is active before prescribing. The Utah Division of Occupational and Professional Licensing (DOPL) license lookup tool is publicly available at dopl.utah.gov.

The ACC/AHA guidelines note that "in clinical practice, the decision to add a PCSK9 inhibitor should be made collaboratively between the patient and the clinician after discussion of cardiovascular risk, potential benefit, and cost" [3]. That conversation can take place via telehealth in Utah.